Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Moodys
UBS
Express Scripts
Queensland Health
Dow
Chinese Patent Office
Covington
Teva

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,211,600

« Back to Dashboard

Which drugs does patent 7,211,600 protect, and when does it expire?

Patent 7,211,600 protects SUTENT and is included in one NDA.

This patent has thirteen patent family members in thirteen countries.
Summary for Patent: 7,211,600
Title:Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
Abstract:The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
Inventor(s): Lipson; Ken (San Mateo, CA), McMahon; Gerald (Kenwood, CA)
Assignee: Sugen Inc. (South San Francisco, CA)
Application Number:11/205,474
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,211,600
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent 7,211,600

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-001 Jan 26, 2006 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB ➤ Sign Up
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-002 Jan 26, 2006 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB ➤ Sign Up
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-004 Mar 31, 2009 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB ➤ Sign Up
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-003 Jan 26, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Argus Health
Covington
Farmers Insurance
Johnson and Johnson
Chubb
Express Scripts
Citi
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.